Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.8K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perioperative Safety and Early Oncologic Outcomes of Salvage Irreversible Electroporation for Radiorecurrent Prostate Cancer.

The Prostate·2026
Same author

Immediate Release of Prostate Biopsy Results: Perspectives From Patients and Providers.

Urology·2026
Same author

Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer.

Cancer treatment reviews·2025
Same author

The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer.

NPJ precision oncology·2025
Same author

Lack of Diversity in Minimally Invasive Bladder Outlet Surgery Among Urologists in the United States.

Rhode Island medical journal (2013)·2025
Same author

Lessons Learned From a Mindfulness Intervention Study in Men With Newly Diagnosed Prostate Cancer.

The Prostate·2025

Related Experiment Video

Updated: Apr 17, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Neoadjuvant and Adjuvant Therapies for High-Risk Prostate Cancer.

Suhas Penukonda1, Elias Hyams2, Gyan Pareek3

  • 1Department of Urology, Brown University, Providence, RI 02905, USA.

The Urologic Clinics of North America
|April 15, 2026
PubMed
Summary

High-risk localized prostate cancer (HR-PCa) management is evolving. Current evidence favors individualized adjuvant therapy and early salvage radiotherapy over routine adjuvant approaches for better outcomes.

Keywords:
AdjuvantChemohormonal therapyHigh-risk prostate cancerNeoadjuvantSecond-generation hormonal therapy

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Related Experiment Videos

Last Updated: Apr 17, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.3K

Area of Science:

  • Oncology
  • Urology

Background:

  • High-risk localized prostate cancer (HR-PCa) has a significant risk of recurrence post-treatment.
  • Current treatment paradigms require optimization for improved patient outcomes.

Purpose of the Study:

  • To evaluate the current and emerging roles of neoadjuvant and adjuvant therapies in HR-PCa.
  • To discuss strategies for personalizing treatment to balance oncologic control and quality of life.

Main Methods:

  • Review of current literature on neoadjuvant and adjuvant therapies for HR-PCa.
  • Analysis of recent clinical trial data regarding radiotherapy and systemic therapies.
  • Discussion of future directions including molecular profiling and advanced imaging.

Main Results:

  • Neoadjuvant therapies show promise in improving pathologic response but lack proven survival benefits.
  • Recent data suggest early salvage radiotherapy is preferred over routine adjuvant radiotherapy for HR-PCa.
  • Androgen deprivation therapy, AR pathway inhibitors, and chemotherapy are key components of systemic treatment.

Conclusions:

  • Treatment for HR-PCa is shifting towards individualized approaches.
  • Personalized selection of neoadjuvant and adjuvant therapies is crucial for optimizing outcomes.
  • Ongoing research aims to refine patient stratification and treatment strategies for HR-PCa.